RPRX vs RVMD
Royalty Pharma plc and Revolution Medicines, Inc., both Healthcare
Revolution Medicines, Inc. is the larger company at $38B against $31B. Over the past year RVMD returned +336% against +59% for RPRX. The RyuScore puts RPRX ahead, 52 against 7 out of 100.
| Figure | RPRX | RVMD |
|---|---|---|
| Last close | $56.90 | $190 |
| Market cap | $31B | $38B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 30.3 | n/a |
| 1-year return | +59% | +336% |
| 5-year return | +61% | +542% |
| RyuScoresector-relative, 1–10 | 52/100 | 7/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Royalty Pharma plc
Revenue of $674M in Q2 2026, net income $18M. Its largest reported line is Financial Royalty Assets, 95% of the disclosed total.
Revolution Medicines, Inc.
Open these two in the interactive comparison to add more names, change the period or see the correlation.